<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01427322</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-13711</org_study_id>
    <secondary_id>NCI-2011-02734</secondary_id>
    <nct_id>NCT01427322</nct_id>
  </id_info>
  <brief_title>Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease</brief_title>
  <official_title>A Randomized Study of Lapatinib With Radiation Versus Radiation Alone in Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lapatinib will prevent radiation-induced increase in Transforming Growth Factor alpha (TGFα),&#xD;
      an important growth factor in cancer cell recovery after ionizing irradiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lapatinib is an orally bioavailable small molecule inhibitor of ERBB1 and ERBB2 (HER2). It is&#xD;
      currently indicated for use in patients with HER2 over-expressing metastatic breast cancer.&#xD;
      Serum increases in TGFα can have growth potentiating effects on distant sites of metastatic&#xD;
      disease. Palliative irradiation paradoxically may promote distant tumor growth; blocking&#xD;
      shedding of TGFα from irradiated tumors may prevent this effect and improve the therapeutic&#xD;
      index of radiation therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual&#xD;
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TGFalpha</measure>
    <time_frame>3 years</time_frame>
    <description>Blockade of the ERBB1 receptor will abrogate increases in TGFalpha in response to radiation therapy. We will compare serum changes in TGFalpha between the lapatinib and control groups for patients receiving radiotherapy for stage IV epithelial-derived cancer.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Epithelial Cancer</condition>
  <arm_group>
    <arm_group_label>lapatinib + radiation therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lapatinib given orally 2-4 hours prior to first fraction of radiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No therapy prior to radiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiation therapy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>given orally 2-4 hours before first fraction of radiation therapy</description>
    <arm_group_label>lapatinib + radiation therapy</arm_group_label>
    <other_name>GW572016</other_name>
    <other_name>Tykerb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>Standard radiation therapy</description>
    <arm_group_label>No therapy prior to radiation</arm_group_label>
    <arm_group_label>lapatinib + radiation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of stage IV epithelial-derived cancer requiring palliative radiation. Patients&#xD;
             with sarcoma, lymphoma, myeloma or neuroendocrin cancers are not eligible.&#xD;
&#xD;
          -  Evidence of metastatic disease&#xD;
&#xD;
          -  Recommendation by patient's radiation oncologist to receive palliative external beam&#xD;
             radiation for metastases -- minimum fraction size of 3 Gy.&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Patients may be undergoing concurrent therapy with GNRH agonists or combined androgen&#xD;
             blockade or anti-estrogen hormonal therapy for breast cancer, as these are standard&#xD;
             care for advanced prostate and some breast cancers respectively.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contraindication to lapatinib treatment.&#xD;
&#xD;
          -  Prior radiation therapy within 30 days of the start of the planned course of&#xD;
             treatment.&#xD;
&#xD;
          -  Prior cytotoxic chemotherapy within 4-2 weeks of planned first dose of radiation.&#xD;
             Persistent grade 2 or greater non-hematologic toxicity (other than neuropathy) from&#xD;
             cytotoxic chemotherapy regardless of interval since last dose. Persistent grade 3 or&#xD;
             greater hematologic toxicity (other than lymphopenia) reglardless of interval since&#xD;
             last dose.&#xD;
&#xD;
          -  Prior administration of an ERBB1 or ERK1/2 inhibitor within 30 days of the start of&#xD;
             the planned course of treatment.&#xD;
&#xD;
          -  Patients with a medical necessity to continue active therapy with CYP3A4 strong&#xD;
             inhibitors or inducers. The concomitant use of strong CYP3A4 inhibitors should be&#xD;
             avoided (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir,&#xD;
             nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole,&#xD;
             aprepitant). Grapefruit may also increase plasma concentrations of lapatinib and&#xD;
             should be avoided. Once the strong inhibitor or inducer is discontinued, a washout&#xD;
             period of approximately 1 week should be allowed before the lapatinib administration.&#xD;
             If a patient is unable to discontinue these medications, they are not eligible for&#xD;
             enrollment.&#xD;
&#xD;
          -  Concurrent administration of any other investigational agents.&#xD;
&#xD;
          -  Uncontrolled concurrent illness including, but not limited to ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, active hepatic or biliary disease with a Child-Pugh class of B or C, or&#xD;
             psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements or that would interfere with accomplishing the study objectives.&#xD;
&#xD;
          -  Pregnant or nursing. Women of childbearing potential must have a negative pregnancy&#xD;
             test performed within 7 days prior to the start of treatment. Women of childbearing&#xD;
             potential and men must agree to use a medically accepted form of birth control for the&#xD;
             duration of study participation. Men must agree to use a medically accepted form of&#xD;
             birth control for 4 months following completion of study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew S. Poklepovic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massey Cancer Center, Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.massey.vcu.edu/</url>
    <description>Massey Cancer Center</description>
  </link>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>August 30, 2011</study_first_submitted>
  <study_first_submitted_qc>August 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2011</study_first_posted>
  <last_update_submitted>July 6, 2015</last_update_submitted>
  <last_update_submitted_qc>July 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lapatinib</keyword>
  <keyword>radiation therapy</keyword>
  <keyword>metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lapatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

